Journal of Clinical Epidemiology
Volume 53, Issue 9 , Pages 888-894 , September 2000

Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)? An evaluation of the risks and benefits of TPA from the patient's perspective

  • Daren K Heyland

      Affiliations

    • Department of Medicine, Queen's University, Kingston, Ontario, Canada
    • Corresponding Author InformationCorresponding author. Angada 3, Kingston General Hospital, Kingston, Ontario, Canada K7L 2V7. Tel: 613-549-6666x3339; fax: 613-548-2577.
    • ,
  • Amiram Gafni

      Affiliations

    • Center for Health Economics and Policy Analysis and Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    • ,
  • Mitchell A.H Levine

      Affiliations

    • Center for Evaluation of Medicines, St. Joseph's Hospital, Hamilton, Ontario, Canada

Received 27 August 1998 ,Revised 16 July 1999 ,Accepted 28 October 1999.

References 

  1. Ridker PM, O'Donnell C, Marder VJ, Hennekens CH. Large scale trials of thrombolytic therapy for acute myocardial infarction (GISSI-2, ISIS-3, and GUSTO-1). Ann Intern Med. 1993;119:530–532[Editorial]
  2. Lee KL, Califf RM, Simes J, Van de Werf F, Topol EJ, for the GUSTO investigators. Holding GUSTO up to the light. Ann Intern Med 1994;120:876–881.
  3. Ricker PM, O'Donnell C, Murder V, Hennekens CH. A response to “Holding GUSTO up to the light.”. Ann Intern Med. 1994;120:882–885
  4. Farkouh ME, Lang JD, Sackett DL. Thrombolytic agents (The science of the art of choosing the better treatment). Ann Intern Med. 1994;120:886–888[Editorial]
  5. The GUSTO investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–682
  6. Lee TH. Cost effectiveness of tissue Plasminogen Activator. N Engl J Med. 1995;332:1443–1444[Editorial]
  7. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, et al.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332:1418–1424
  8. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med. 1995;10:321–330
  9. O'Brien B, Heyland DK, Richardson WS, Levine M, Drummond MF, for the Evidence-Based Medicine Working Group . User's Guides to the medical literature. XI. How to use an economic analysis of clinical practice (B. What are the results and will they help me in caring for my patients?). JAMA. 1997;277:1802–1806
  10. Eddy D. Anatomy of a decision. JAMA. 1990;263:441–444
  11. Kassirer JP. Incorporating patient's preferences into medical decisions. N Engl J Med. 1994;330:1895–1896[Editorial]
  12. Levine MN, Gafni A, Markham B, MacFarlane D. A bedside decision instrument to elicit a patient's preferences concerning adjuvant chemotherapy for breast cancer. Ann Intern Med. 1992;117:53–58
  13. Whelan TJ, Levine MN, Gafni A, et al.  Breast irradiation post lumpectomy (Development and evaluation of a decision instrument). J Clin Oncology. 1995;13:847–853
  14. Sebban C, Browman G, Gafni A, et al.  Design and validation of a bedside instrument to elicit a patient's preference concerning allogenic bone marrow transplantation in chronic myeloid leukemia. Am J Hematol. 1995;48:221–227
  15. Elit LM, Levine MN, Gafni A, Whelan TJ, Doig G, Streiner DL, et al. Patient's preferences for therapy in advanced epithelial ovarian cancer (Developing, testing and application of a bedside decision instrument). Gynecologic Oncologic Journal. 1996;62:329–335
  16. Fibrinolytic Therapy Trialist's Collaborative Group . Indications for fibrinolytic therapy in suspected acute myocardial infarction (Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients). Lancet. 1994;343:311–322
  17. Stanek EJ, Cheng JWM, Peeples PJ, Simko RJ, Spinler SA. Patient preferences for thrombolytic therapy in acute myocardial infarction. Med Decis Making. 1997;17:464–471
  18. Torrance GW. Health states worse than death. In: won Eimeren W, Englbrecht R, Flagle CD, editors. Third International Conference on Systems Science Health care. Berlin, Germany: 1984. Springer Verlag.
  19. Mehrez A, Gafni A. The optimal treatment strategy—a patient's perspective. Management Science. 1987;33:1602–1612
  20. Bell DE, Farquhar PH. Perspective on utility theory. Operations Research. 1986;34:179–183
  21. Fishburn PC. Expected utility (an anniversary and a new era). Journal of Risk and Uncertainty. 1988;1:267–288
  22. Machina MJ. Choice under uncertainty (problems solved and unsolved). Economics Perspective. 1987;1:121–154
  23. Tversky A, Kahneman D. Judgement under certainty (heuristics and biases). Science. 1974;185:1124–1131
  24. Kahneman D, Tversky A. Prospect theory (an analysis of decisions under risk). Econometrica. 1979;47:262–291
  25. O'Brien B, Goeree R, Gafni A, Torrance GW, Pauly MV, Erder H, et al. Assessing the value of a new pharmaceutical (a feasibility study of contingent valuation in managed care). Medical Care. 1998;36:370–384

☆ Dr. Heyland is a Career Scientist with the Ministry of Health of Ontario. This Study not funded.

☆☆ Evaluation Study as of July 3, 1999.

PII: S0895-4356(99)00214-0

Journal of Clinical Epidemiology
Volume 53, Issue 9 , Pages 888-894 , September 2000

Article Tools

* Image Usage & Resolution